How does the small molecule AGX51 cause the degradation of ID proteins?

Project specs

Format

2D/3D

Contact

Robert Benezra

Country

USA

Funding agency

NIH, Breast Cancer Research Foundation, Angiogenex, Inc., Memorial Sloan Kettering Cancer Center

Length

01:00

Summary

Together with Angiogenex, Inc. Dr Robert Benezra, Member of the Cancer Biology and Genetics Program at Memorial Sloan Kettering Cancer Center, has identified a small molecule, AGX51, that inhibits ID proteins and disrupts the cellular pathways by which cancers repropagate, and could therefore be an important new anti-tumour therapy.

Researcher Profile

Robert Benezra, PhD, is a Member of the Cancer Biology and Genetics Program at Memorila Sloan Ketter Cancer Center. His work over the past 30 years there has identified the importance of ID proteins in development and their reactivation in a variety of cancers. Recent targeting of ID proteins by small molecules with the help of Angiogenex, Inc has led to the development of novel targeted therapies being readied for clinical application.